Literature DB >> 31790924

Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease.

Daniel Grün1, Valerie C Zimmer2, Jil Kauffmann3, Jörg Spiegel4, Ulrich Dillmann5, Andreas Schwiertz6, Klaus Faßbender7, Mathias Fousse8, Marcus M Unger9.   

Abstract

Entities:  

Keywords:  COMT-Inhibitor; Faecalibacterium prausnitzii; Fecal butyrate; Gut microbiota; Parkinson's disease

Mesh：

Substances：

Year:  2019        PMID： 31790924     DOI： 10.1016/j.parkreldis.2019.11.020

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


× No keyword cloud information.
  4 in total

Review 1.  Novel Pharmacotherapies in Parkinson's Disease.

Authors:  Yousef Tizabi; Bruk Getachew; Michael Aschner
Journal:  Neurotox Res       Date:  2021-05-18       Impact factor: 3.911

Review 2.  Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders.

Authors:  Piyush Padhi; Carter Worth; Gary Zenitsky; Huajun Jin; Kumar Sambamurti; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Front Neurosci       Date:  2022-02-25       Impact factor: 4.677

3.  A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.

Authors:  Shih-Chen Fu; Chung-Han Lee; Yi-Chen Hsieh; Pei-Hua Wu; Sheng-Hsuan Lin; Hsiuying Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-04-05       Impact factor: 6.073

Review 4.  Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson's Disease.

Authors:  Wolfgang H Jost
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-06       Impact factor: 2.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.